<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438984</url>
  </required_header>
  <id_info>
    <org_study_id>2140.00</org_study_id>
    <secondary_id>NCI-2010-01280</secondary_id>
    <secondary_id>R21CA128283</secondary_id>
    <nct_id>NCT00438984</nct_id>
  </id_info>
  <brief_title>Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Phase I Study To Evaluate Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cell Clones Following Cyclophosphamide Conditioning For Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate&#xD;
      the immune system in different ways and stop tumor cells from growing. Drugs used in&#xD;
      chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells or by stopping them from dividing. Cyclophosphamide may&#xD;
      also stimulate the immune system in different ways and stop tumor cells from growing.&#xD;
      Aldesleukin may stimulate white blood cells to kill tumor cells. Giving therapeutic&#xD;
      autologous lymphocytes together with cyclophosphamide and aldesleukin may be an effective&#xD;
      treatment for melanoma.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects of giving therapeutic autologous&#xD;
      lymphocytes together with cyclophosphamide and aldesleukin in treating patients with stage IV&#xD;
      melanoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the safety and toxicity of cellular adoptive immunotherapy in melanoma patients&#xD;
      receiving autologous CD8+ antigen-specific T cell clones following cyclophosphamide&#xD;
      conditioning and post-infusion IL-2.&#xD;
&#xD;
      II. To assess the duration of in vivo persistence of adoptively transferred CD8+ T cell&#xD;
      clones.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the antitumor effect of adoptively transferred CD8+ antigenspecific cytotoxic t&#xD;
      lymphocytes (CTL) clones following cyclophosphamide conditioning and post-infusion IL-2.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients are assigned 1of 2 treatment cohorts.&#xD;
&#xD;
      All patients receive high-dose cyclophosphamide intravenously (IV) on days -3 and -2 and&#xD;
      autologous antigen-specific cytotoxic CD8+ T lymphocyte clones IV over 30-60 minutes on day&#xD;
      0.&#xD;
&#xD;
      COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin&#xD;
      subcutaneously (SC) twice daily on days 0-14.&#xD;
&#xD;
      COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose&#xD;
      aldesleukin IV 3 times daily on days 0-5.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks, 8 weeks, and every&#xD;
      3 months thereafter for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The identification of a CY/IL-2 regimen that is considered to be safe</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The identification of a CY/IL-2 regimen (among those considered safe) which yields the greatest effect on the duration of in vivo persistence of adoptively transferred CTL clones</measure>
    <time_frame>Baseline, 4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.&#xD;
COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.&#xD;
COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>AL</other_name>
    <other_name>Autologous Lymphocytes</other_name>
    <other_name>autologous T cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given IV or SC</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Optional correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>immunological laboratory methods</other_name>
    <other_name>laboratory methods, immunological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, immunosuppressive, lymphocytes)</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological documentation of melanoma concurrent with the diagnosis of&#xD;
             metastatic disease&#xD;
&#xD;
          -  Expression of HLA-A2, B44, or A3 as determined by Fred Hutchinson Cancer Research&#xD;
             Center (FHCRC) human leukocyte antigen (HLA) typing lab&#xD;
&#xD;
          -  Zubrod performance status of 0-1&#xD;
&#xD;
          -  Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic&#xD;
             imaging (X-ray, CT scan)&#xD;
&#xD;
          -  Normal cardiac stress test within 182 days prior to enrollment is required of all&#xD;
             patients over 50 years old or those with an abnormal electrocardiogram (ECG), any&#xD;
             history of cardiac disease, a family history of cardiac disease, hypercholesterolemia&#xD;
             or hypertension&#xD;
&#xD;
          -  FOR LEUKAPHERESIS:&#xD;
&#xD;
          -  Pulse &gt; 45 or &lt; 120&#xD;
&#xD;
          -  Weight &gt;= 45 kg&#xD;
&#xD;
          -  White blood cell count (WBC) &gt;= 3,000&#xD;
&#xD;
          -  Temperature =&lt; 38C (=&lt; 100.4 F)&#xD;
&#xD;
          -  Hematocrit (HCT) &gt;= 30%&#xD;
&#xD;
          -  Platelets &gt;= 100,000&#xD;
&#xD;
          -  FOR T CELL INFUSION: Patients must be willing and able to discontinue the use of all&#xD;
             anti-hypertensive medications 24 hours prior to and during IL-2 therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women, nursing mothers, men or women of reproductive ability who are&#xD;
             unwilling to use effective contraception or abstinence; women of childbearing&#xD;
             potential must have a negative pregnancy test within two weeks prior to entry&#xD;
&#xD;
          -  Serum creatinine &gt; 1.6 mg/dL or Creatinine clearance &lt; 75 ml/min&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) &gt; 150 IU or &gt; 3x upper limit of normal&#xD;
&#xD;
          -  Bilirubin &gt; 1.6 mg/dL&#xD;
&#xD;
          -  Prothrombin time &gt; 1.5 x control&#xD;
&#xD;
          -  Clinically significant pulmonary dysfunction, as determined by medical history and&#xD;
             physical exam; patients so identified will undergo pulmonary functions testing and&#xD;
             those with forced expiratory volume in one second (FEV1) &lt; 2.0 L or carbon monoxide&#xD;
             diffusing capacity (DLco) (corr for Hgb) &lt; 75% will be excluded&#xD;
&#xD;
          -  Significant cardiovascular abnormalities as defined by any one of the following:&#xD;
&#xD;
          -  Congestive heart failure;&#xD;
&#xD;
          -  Clinically significant hypotension;&#xD;
&#xD;
          -  Symptoms of coronary artery disease;&#xD;
&#xD;
          -  Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy;&#xD;
&#xD;
          -  Ejection fraction &lt; 50 % (echocardiogram or multi gated acquisition scan [MUGA])&#xD;
&#xD;
          -  Symptomatic central nervous system metastases greater than 1 cm at the time of&#xD;
             therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system&#xD;
             (CNS) metastases without significant edema may be considered for treatment; if&#xD;
             sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be&#xD;
             performed if more than 3 weeks have elapsed from the last scan; patients will not be&#xD;
             treated if CNS lesions are &gt; 1 cm or if patient is symptomatic from brain metastasis&#xD;
&#xD;
          -  Patients with active infections or oral temperature &gt; 38.2 C within 72 hours of study&#xD;
             entry or systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  Chemotherapeutic agents (standard or experimental), radiation therapy, or other&#xD;
             immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with&#xD;
             bulky disease may undergo cytoreductive chemotherapy but treatment will be&#xD;
             discontinued at least 3 weeks prior to T cell therapy)&#xD;
&#xD;
          -  Clinically significant autoimmune disorders or conditions of immunosuppression;&#xD;
             patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency&#xD;
             virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be&#xD;
             recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this&#xD;
             study; virology testing will be done within 6 months of T cell infusion; the severely&#xD;
             depressed immune system found in these infected patients and the possibility of&#xD;
             premature death would compromise study objectives&#xD;
&#xD;
          -  FOR T CELL INFUSION: Patients with active infections or oral temperature &gt; 38.2 C&#xD;
             within 72 hours of study entry or systemic infection requiring chronic maintenance or&#xD;
             suppressive therapy&#xD;
&#xD;
          -  FOR T CELL INFUSION: Chemotherapeutic agents (standard or experimental), radiation&#xD;
             therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell&#xD;
             therapy&#xD;
&#xD;
          -  FOR T CELL INFUSION: Current treatment with steroids&#xD;
&#xD;
          -  FOR T CELL INFUSION: Patients must not be receiving any other experimental drugs&#xD;
             within 3 weeks of the initiation of the protocol and must have recovered from all side&#xD;
             effects of such therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <name_title>Yee, Cassian</name_title>
    <organization>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

